Pacific Biosciences of California (PACB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Pacific Biosciences of California (PACB) is Neutral.

The composite score behind that read is +0.06, weighing +0.15 of bullish evidence against -0.21 bearish.

Pacific Biosciences of California last closed at $2.33, +1.30% on the session.

Against the IVW growth benchmark the position is +0.50% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

18 graded predictions for PACB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Pacific Biosciences of California in the 0th percentile on return on equity, where 100 is best.

Pacific Biosciences of California is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $714.91M.

StockMap tracks Pacific Biosciences of California as the 32nd largest of the 41 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 37 Neutral, 2 Moderate Outperform and 2 Moderate Underperform.

On that composite Pacific Biosciences of California ranks 23rd of 41 in the group, against a group median of +0.06.